- R2RL25, John Bull Building, Research Way, Plymouth Science Park, Plymouth, Devon, PL6 8BU
- +44 1752 437308
- oleg.anichtchik@plymouth.ac.uk
Profiles
Dr Oleg Anichtchik
Honorary Lecturer in Clinical Neurobiology
Faculty of Medicine and Dentistry
Role
2013 - present - Principal Investigator, Lecturer, Department of Clinical Neurobiology, Plymouth University Schools of Medicine and Dentistry.
Qualifications
Education:
2001 - Ph.D. degree was awarded by the Faculty of Mathematics and Natural Sciences, Åbo Akademi University, Turku, Finland;
1996 - M.D. degree was awarded by the Faculty of the General Medicine, Grodno State Medical Institute, Grodno, Belarus.
Previously held positions:
2010 - 2013 - Alzheimer Research UK (ARUK) Senior Research fellow, Centre for Brain Repair, University of Cambridge, United Kingdom ;
2009 - 2012 - Clare College Research Associate, University of Cambridge, United Kingdom ;
2007-2010 - Postdoctoral fellow at Cambridge Centre for Brain Repair, University of Cambridge, United Kingdom;
2005 - 2007 - Senior Research Associate, Daniolabs Ltd, Cambridge, United Kingdom;
2001 - 2004 - Finnish Academy of Sciences postdoctoral fellow, Institute of Biomedicine, Department of Anatomy, University of Helsinki, Finland;
1995 - 1996 - Junior researcher at the Laboratory of Morphology and Neurochemistry, Institute of Biochemistry, Academy of Sciences of Belarus, Grodno, Belarus.
Professional membership
Fellow of the Higher Education Academy, UK;
Member of the Society for Neuroscience, USA;
Member of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), USA.
Research interests
Understanding mechanisms of insoluble protein aggregates formation and cellular degeneration in the human brain is one of the most pressing questions of clinical neurobiology. We are trying to understand the process of alpha-synuclein aggregation in the development of neurodegenerative disorders such as Parkinson's disease and dementia with Lewy bodies. In particular, we are looking for the reasons of a selective vulnerability of neurons to the toxic insult caused by aggregating proteins and whether dis-aggregating strategies could be beneficial in these conditions. To address this, classical neuromorphology, biochemistry and cell biology techniques are used in the range of in vitro and in vivo models, including human post-mortem studies, animal models of neurodegeneration and cell culture assays.
Grants & contracts
2016 - Alzheimer’s Research UK network centre grant, £25,000 (PI)
2016 - BRACE Alzheimer's Research, £86,000 (PI)
2016 - Northcott Devon Medical Foundation (UK), £7,000 (PI)
2015 - British Neuropathological Society, £5,000 (PI)
2014 - Alzheimer’s Research UK network centre grant , £25,000 (PI)
Research groups
Key publications are highlighted
Journals
Articles
2018
'White matter tauopathy: Transient functional loss and novel myelin remodeling'
Glia
, DOI
PEARL
2017
'Accumulation of beta-synuclein in cortical neurons is associated with autophagy attenuation in the brains of dementia with Lewy body patients'
Brain Research
1681,
1-13
, DOI
PEARL
2015
'Behavioural deficits in transgenic mice expressing human truncated (1–120 amino acid) alpha-synuclein'
Experimental Neurology
264,
8-13
, DOI
2014
'Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review'
Acta Neurol Scand
130,
(2)
59-72
, DOI
2013
'Synaptic dysfunction in synucleinopathies'
CNS Neurol Disord Drug Targets
12,
(8)
1094-1100
2013
'Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra'
Exp Neurol
248,
541-545
, DOI
2011
'Expression of PINK1 in the brain, eye and ear of mouse during embryonic development (vol 41, pg 73, 2011)'
JOURNAL OF CHEMICAL NEUROANATOMY
42,
(1)
99-100
, DOI
2011
'Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice'
Neurodegenerative Diseases
8,
(6)
430-437
, DOI
2010
'SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease'
Brain
133,
(Pt 7)
2032-2044
, DOI
2010
'Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice'
PLoS One
5,
(1)
, DOI
2009
'Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases'
Br J Pharmacol
157,
(1)
118-129
, DOI
2009
'Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish'
J Neurochem
109,
(2)
403-415
, DOI
2009
'Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish'
J Neurosci
29,
(5)
1343-1349
, DOI
2008
'Loss of PINK1 function affects development and results in neurodegeneration in zebrafish'
J Neurosci
28,
(33)
8199-8207
, DOI
2007
'Identification of zebrafish histamine H1, H2 and H3 receptors and effects of histaminergic ligands on behavior'
Biochem Pharmacol
73,
(8)
1205-1214
, DOI
2006
'Distinct structure and activity of monoamine oxidase in the brain of zebrafish (Danio rerio)'
J Comp Neurol
498,
(5)
593-610
, DOI
2004
'Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine'
J Neurochem
88,
(2)
443-453
2004
'Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine'
JOURNAL OF NEUROCHEMISTRY
88,
(2)
443-453
, DOI
2003
'Expression of the H3 receptor in the developing CNS and brown fat suggests novel roles for histamine'
Mol Cell Neurosci
24,
(3)
614-622
2003
'Increased brain histamine H3 receptor expression during hibernation in golden-mantled ground squirrels'
BMC Neurosci
4,
, DOI
PEARL
2003
'Modulation of the histaminergic system and behaviour by α-fluoromethylhistidine in zebrafish'
Journal of Neurochemistry
86,
(2)
432-441
, DOI
2003
'Changes in hippocampal histamine receptors across the hibernation cycle in ground squirrels'
Hippocampus
13,
(6)
745-754
, DOI
2002
'Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy'
J Neurochem
81,
(5)
954-960
2002
'Low brain histamine content affects ethanol-induced motor impairment'
Neurobiol Dis
9,
(1)
94-105
, DOI
2001
'Distribution and Modulation of Histamine H3 Receptors in Basal Ganglia and Frontal Cortex of Healthy Controls and Patients with Parkinson's Disease'
Neurobiology of Disease
8,
(4)
707-716
, DOI
2000
'Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats'
Eur J Neurosci
12,
(11)
3823-3832
2000
'Identification of a Histamine H3-like Receptor in the Zebrafish (Danio rerio) Brain'
Journal of Neurochemistry
75,
(2)
718-724
, DOI
2000
'An altered histaminergic innervation of the substantia nigra in Parkinson's disease'
Exp Neurol
163,
(1)
20-30
, DOI
2000
'The histaminergic system in the brain: structural characteristics and changes in hibernation'
J Chem Neuroanat
18,
(1-2)
65-74
1999
'Alcohol-histamine interactions'
Alcohol Alcohol
34,
(2)
141-147
1998
'Brain histamine in pathophysiological conditions and brain diseases'
Pharmacochemistry Library
30,
(C)
243-253
, DOI
Books
2001
Histaminergic Regulation of the Nigrostriatal System in Parkinson's Disease and a Rat Model of Parkinsonism.
Chapters
1998
'The Histamine H3 Receptor'
in Leurs R; Timmerman H
The Histamine H3 Receptor
Elsevier
Conference Papers
2009
'Chronic oral administration of low doses of rotenone reproduces Braak's Parkinson's staging'
228-229
2009
'Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice'
S42-S43
2000
'mRNA expression of three histamine receptors in the human prefrontal cortex and thalamus'
409-409
2000
'The histaminergic innervation and histamine H3 receptors in basal ganglia of parkinsonian brains'
471-471